Description
Seeking people aged 2 and older with Dystrophic Epidermolysis Bullosa with confirmed mutation(s) of the Type 7 collagen (COL7A1) gene for a study of an investigational drug for wound healing.
Overview
Participants in this study will have blood and skin samples collected for use in making the investigational drug that will be injected back into their skin during 2 and maybe as many as 4 study visits. During the first 15 months of the study there are about 11 study visits. Afterward, there may be annual follow-up study visits and blood tests for the remaining 14 years.
What we're hoping for
We are studying if an investigational drug made using the skin cells of the person being treated (cell therapy) is safe and effective in increasing collagen and preventing blisters and wounds for people with dystrophic epidermolysis bullosa (DEB).
Additional Information
ClinicalTrials.gov Identifier: Not Available